| Name | Title | Contact Details |
|---|
Procyrion is developing the first catheter-deployed circulatory assist device intended for long-term use. The Procyrion device will be the first minimally invasive tool for cardiologists to treat over 1M NYHA Class III and early class IV heart failure (HF) patients in the US who have few therapeutic options. In partnership with Texas Heart Institute, Procyrion is currently conducting preclinical testing of the Procyrion device.
When it comes to treating addiction to opioids and other substances, there`s no single magic bullet. Rather, it takes a combination of tools to surround patients with care and keep them on the road to recovery. Spero Health delivers outpatient care to treat patients close to home in their own environments so they can cope with life as they overcome addiction. We create an individualized treatment plan for each patient using a pioneering, proven, three-pronged approach: 1. Evidence-based physician services • Physician visit • Mental and physical health screenings • Individualized recovery plan • Medication-assisted treatment, which may include Suboxone® or Vivitrol, to ease the symptoms of withdrawal and craving for opioids 2. Counseling • Individual and/or group sessions that provide safe places to talk and valuable support to help patients achieve lasting recovery 3. Recovery Support Services • Assistance in finding employment, housing, healthcare, child care, legal services, transportation and more • Wellness programs, such as smoking cessation, sleep hygiene and nutrition • Education to help patients better understand their disorder and the steps toward a successful recovery
BSN medical is a global medical device company specializing in the areas of Orthopaedics which focuses on bandaging, cast tapes, Plaster of Paris, splinting systems, orthopaedic soft goods, fracture bracing, and thermoplastics, Phlebology which serves
Prudental Laboratories Inc is a Santa Ana, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Motif Neurotech is a clinical-stage company leading the development of minimally invasive neuromodulation therapeutics for mental health. The company`s lead product, for treatment resistant depression (TRD), is a miniature implant that is designed to treat TRD by increasing activity in the prefrontal cortex. Studies over 20 years show stimulation of the pre-frontal cortex effectively treats treatment resistant depression without the side effects of anti-depressants. However, existing brain stimulation treatments like transcranial magnetic stimulation (TMS) can be expensive and challenging for patients to access, with daily treatments required for six weeks that may need to be repeated. Human and large animal studies show Motif`s prototype stimulates target brain areas like TMS, and the company is preparing to begin clinical trials of their first chronic implants in 2025. Motif`s implant is enabled by patent-pending wireless magnetoelectric power transfer developed at Rice University. Motif`s founders and key team members are clinical, medical device and academic experts with over 5,000 surgical procedures and decades of medical device experience.